Endo Health's Aveed testosterone injection approved by FDA Endo's operating company Endo Pharmaceuticals received FDA approval of Aveed, testosterone undecanoate, injection for the treatment of adult men with a deficiency or absence of the male hormone testosterone. Aveed is a new prescription medicine indicated to produce serum testosterone levels in the normal range by administration of a single 3-mL intramuscular injection. It is expected to be available in early March.
Endo rallies amid talk of conference cancellation Shares of Endo International are rallying 2% amid talk the company cancelled out of Leerink's conference next week. Endo has no events listed on its website and Bloomberg just reported that according to sources, the company cancelled its appearance at the conference. Shares of Endo are up $1.25 to $55.40 in afternoon trading.